Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daichi Inoue

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
Blood|June 4, 2020
HHEX promotes myeloid transformation in cooperation with mutant ASXL1Reina Takeda, Shuhei Asada, Sung-Joon Park, et al.
Nature|October 11, 2019
Spliceosomal disruption of the non-canonical BAF complex in cancerDaichi Inoue, Guo-Liang Chew, Bo Liu, et al.
Nature Cancer|October 23, 2023
Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemiaKatherine Knorr, Jahan Rahman, Caroline Erickson, et al.
Journal of Biochemistry|November 22, 2015
Novel working hypothesis for pathogenesis of hematological malignancies: combination of mutations-induced cellular phenotypes determines the disease (cMIP-DD)Toshio Kitamura, Naoko Watanabe-Okochi, Yutaka Enomoto, et al.
Nature Communications|December 15, 2023
BRD9 determines the cell fate of hematopoietic stem cells by regulating chromatin stateMuran Xiao, Shinji Kondo, Masaki Nomura, et al.
Cancer Cell|August 15, 2018
Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene MutationsStanley Chun-Wei Lee, Khrystyna North, Eunhee Kim, et al.
The Journal of Clinical Investigation|June 20, 2018
Oncogenic TRK fusions are amenable to inhibition in hematologic malignanciesJustin Taylor, Dean Pavlick, Akihide Yoshimi, et al.
Blood|June 16, 2022
Aberrant EVI1 splicing contributes to EVI1-rearranged leukemiaAtsushi Tanaka, Taizo A Nakano, Masaki Nomura, et al.
Blood Cancer Journal|September 22, 2021
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidineNora E Rahmani, Nandini Ramachandra, Srabani Sahu, et al.
Cancer Discovery|July 29, 2022
Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic TransformationSisi Chen, Rahul S Vedula, Antonio Cuevas-Navarro, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Blood|June 4, 2020
HHEX promotes myeloid transformation in cooperation with mutant ASXL1Reina Takeda, Shuhei Asada, Sung-Joon Park, et al.
Nature|October 11, 2019
Spliceosomal disruption of the non-canonical BAF complex in cancerDaichi Inoue, Guo-Liang Chew, Bo Liu, et al.
Nature Cancer|October 23, 2023
Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemiaKatherine Knorr, Jahan Rahman, Caroline Erickson, et al.
Journal of Biochemistry|November 22, 2015
Novel working hypothesis for pathogenesis of hematological malignancies: combination of mutations-induced cellular phenotypes determines the disease (cMIP-DD)Toshio Kitamura, Naoko Watanabe-Okochi, Yutaka Enomoto, et al.
Nature Communications|December 15, 2023
BRD9 determines the cell fate of hematopoietic stem cells by regulating chromatin stateMuran Xiao, Shinji Kondo, Masaki Nomura, et al.
Cancer Cell|August 15, 2018
Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene MutationsStanley Chun-Wei Lee, Khrystyna North, Eunhee Kim, et al.
The Journal of Clinical Investigation|June 20, 2018
Oncogenic TRK fusions are amenable to inhibition in hematologic malignanciesJustin Taylor, Dean Pavlick, Akihide Yoshimi, et al.
Blood|June 16, 2022
Aberrant EVI1 splicing contributes to EVI1-rearranged leukemiaAtsushi Tanaka, Taizo A Nakano, Masaki Nomura, et al.
Blood Cancer Journal|September 22, 2021
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidineNora E Rahmani, Nandini Ramachandra, Srabani Sahu, et al.
Cancer Discovery|July 29, 2022
Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic TransformationSisi Chen, Rahul S Vedula, Antonio Cuevas-Navarro, et al.
Pageof 9